Search results
Results from the WOW.Com Content Network
There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors. Type 1 diabetes is a disease caused by the lack of insulin. Thus, insulin is the main treatment agent for type 1 and is typically administered via ...
Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [23] [24] [25] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. [26] [27] It can be administered by subcutaneous injection or taken orally.
This is an accepted version of this page This is the latest accepted revision, reviewed on 29 January 2025. Group of endocrine diseases characterized by high blood sugar levels This article is about the common insulin disorder. For the urine hyper-production disorder, see Diabetes insipidus. For other uses, see Diabetes (disambiguation). Medical condition Diabetes Universal blue circle symbol ...
In patients with CVD, GLP-1 agonists were estimated to save money due to fewer cardiovascular incidents. In patients without CVD, the cost per QALY was $9,093. [39] In the United States, cost is the highest barrier to GLP-1 agonist usage and was reported as the reason for discontinuation in 48.6% of U.S. patients who stopped using the drugs. [40]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Unlike type 1 diabetic patients, patients with T2D can still produce insulin, so usually these patients take oral medications first before requiring insulin for diabetic control. [ 2 ] Patient education [ 31 ] and compliance with treatment is very important in managing the disease.